Phase I Trials: We have developed an integrated research program to efficiently and comprehensively identify, evaluate, and develop pharmacotherapeutic treatments for methamphetamine abuse and dependence. A key component of this program is a Phase I human clinical laboratory capable of performing interaction studies needed for assessment of safety and potential efficacy for medications under consideration for study in subsequent Phase II trials. We propose to further develop this research capacity in order to focus on medications or combinations of medications with novel mechanisms of action for the treatment of stimulant abuse and dependence, focusing on methamphetamine. The series of Phase I studies proposed in this project application as a component of the P50 Center continuation will address the following Specific Aims:
Aim 1 : To determine how treatment with an active medication, compared to placebo, alters cardiovascular effects produced by methamphetamine;
Aim 2 : To determine how treatment with an active medication, compared to placebo, alters subjective and reinforcing effects produced by methamphetamine;
Aim 3 : To determine how treatment with an active medication, compared to placebo, alters craving and drug-seeking behavior produced by methamphetamine. A total of four double-blind placebo-controlled studies over five years are planned. Medications to be studied include the cholinesterase inhibitor rivastigmine and the dopamine partial agonist aripiprazole combined with the GABA B agonist baclofen. Two additional studies will be designed based on the outcome of the first two studies and based on scientific developments emerging in the interim to provide safety and preliminary efficacy data for a 3rd phase II trial. A procedure is described for considering evaluation of perindopril and agents acting at the GABA transporter, (tiagabine), that are being studied elsewhere currently for cocaine dependence or other dopamine partial agonists, glutamatergic agents, or compounds from new classes that may be available.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA018185-03
Application #
7390631
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
3
Fiscal Year
2007
Total Cost
$395,977
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Cook, Ryan; Quinn, Brendan; Heinzerling, Keith et al. (2017) Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence. Addiction 112:1077-1085
Mahoney 3rd, James J; De La Garza 2nd, Richard; Jackson, Brian J et al. (2014) The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Res 219:367-71
Verrico, Christopher D; Haile, Colin N; Newton, Thomas F et al. (2013) Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications. Expert Opin Investig Drugs 22:1549-68
Brensilver, Matthew; Heinzerling, Keith G; Shoptaw, Steven (2013) Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev 32:449-60
Brensilver, Matthew; Heinzerling, Keith G; Swanson, Aimee-Noelle et al. (2013) Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. Drug Alcohol Rev 32:96-9
Heinzerling, Keith G; Shoptaw, Steven (2012) Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use. Gend Med 9:112-20
Brensilver, Matthew; Tariq, Shabana; Shoptaw, Steven (2012) Optimizing pain management through collaborations with behavioral and addiction medicine in primary care. Prim Care 39:661-9
Mahoney, James J; Jackson, Brian J; Kalechstein, Ari D et al. (2012) Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers. Int J Neuropsychopharmacol 15:1241-9
Brensilver, Matthew; Heinzerling, Keith G; Swanson, Aimee-Noelle et al. (2012) A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend 125:169-72
Brensilver, Matthew; Heinzerling, Keith G; Swanson, Aimee-Noelle et al. (2012) Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence. Exp Clin Psychopharmacol 20:430-5

Showing the most recent 10 out of 32 publications